Nicergoline


Full Prescribing Info
Dosage/Direction for Use

Oral
Peripheral vascular disease
Adult: 10 mg tid. Maintenance: 5-10 mg tid. Max: Up to 60 mg daily in divided doses.
Renal impairment: Reduce dose.

Oral

Mental deterioration associated with cerebrovascular insufficiency
Adult: 10 mg tid. Maintenance: 5-10 mg tid. Max: Up to 60 mg daily in divided doses.
Renal impairment: Reduce dose.

Intramuscular

Peripheral vascular disease
Adult: 2-4 mg bid.
Renal impairment: Reduce dose.

Intramuscular

Symptoms of mental deterioration associated with cerebrovascular insufficiency
Adult: 2-4 mg bid.
Renal impairment: Reduce dose.

Intravenous

Peripheral vascular disease
Adult: 4-8 mg by slow IV infusion (over 30 min).
Renal impairment: Reduce dose.
Reconstitution:
Dilute in 250 ml saline solution.

Intravenous
Symptoms of mental deterioration associated with cerebrovascular insufficiency
Adult: 4-8 mg by slow IV infusion (over 30 min).
Renal impairment: Reduce dose.
Reconstitution:
Dilute in 250 ml saline solution.
Administration
Should be taken on an empty stomach. Take on an empty stomach.
Special Precautions
Porphyria. Pregnancy.
Adverse Reactions
GI disturbances; hypotension (especially after parenteral admin). Hot flushes, malaise, hyperacidity, nausea, diarrhoea, dizziness, somnolence.
Drug Interactions
May potentiate action of antihypertensives. May increase cardiac depressant effects of propranolol.
Action
Nicergoline is an ergot derivative. It has α-adrenergic blocking activity and produces vasodilatation.
Onset: 1-1.5 hr (oral).
Absorption: Rapidly absorbed from the GI tract (oral).
Distribution: Protein-binding: 82-87%.
Metabolism: Undergoes significant 1st-pass effect.
Excretion: Via urine (80%), via faeces (20%).
ATC Classification
C04AE02 - nicergoline ; Belongs to the class of ergot alkaloids. Used as peripheral vasodilators.
Disclaimer: This information is independently developed by CIMS based on nicergoline from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in